Core Insights - PacBio has joined the 1000 Genomes Long Read Sequencing Project to contribute long-read transcriptome data, enhancing the understanding of human genomics [1][2][3] - The collaboration aims to provide new transcript-level insights from approximately 1,000 samples, supporting accurate gene expression interpretation and regulatory element analysis [2][3] - The project emphasizes transparency and open data, with all sequencing data and analysis pipelines to be publicly available [4][5] Company Contributions - PacBio will utilize its Kinnex RNA kits and Revio sequencing platform to generate full-length isoform sequencing data, with each sample expected to yield around 10 million full-length transcript reads [3] - The collaboration involves key laboratories, including the University of Washington and Johns Hopkins University, to deliver a high-quality RNA resource and scalable bioinformatics pipelines [3][4] Industry Impact - The addition of isoform sequencing to the 1000 Genomes Project is expected to enrich the foundational genomic resource, aiding in diverse applications from basic biology to rare disease diagnostics [3] - The initiative aims to advance equity, access, and innovation in human genetics research, contributing to the fast-growing field of long-read transcriptomics [5]

MENLO PARK, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2025 financial results on Thursday, August 7, 2025, at 5:00 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at https://investor.pacificbiosciences.com/. Date: Thursday, August 7, 2025, at 5:00 pm ET (2:00 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349- ...

Company Performance - Pacific Biosciences of California (PACB) closed at $1.50, with a daily increase of +1.35%, outperforming the S&P 500's gain of 0.28% [1] - The stock has increased by 27.59% over the past month, leading the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37% [1] Earnings Expectations - Analysts expect Pacific Biosciences to report earnings of -$0.18 per share, reflecting a year-over-year growth of 10% [2] - The revenue forecast for the upcoming quarter is $36.46 million, indicating a growth of 1.26% compared to the same quarter last year [2] Full Year Projections - For the full year, earnings are projected at -$0.64 per share and revenue at $155.12 million, showing changes of +22.89% and +0.72% respectively from the previous year [3] Analyst Sentiment - Recent adjustments to analyst estimates indicate positive sentiment towards Pacific Biosciences' business operations and profit generation capabilities [4] - The Zacks Rank system, which assesses stock performance based on estimate changes, currently ranks Pacific Biosciences as 1 (Strong Buy) [6] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 173, placing it in the bottom 30% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Pacific Biosciences of California (PACB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Esti ...

Group 1 - Pacific Biosciences of California (PACB) ended the recent trading session at $1.18, with a +1.72% change from the previous day's closing price, outperforming the S&P 500's daily gain of 0.38% [1] - The company has seen a 5.45% increase in its share price over the past month, while the Medical sector gained 4.64% and the S&P 500 gained 6.6% during the same period [1] Group 2 - The upcoming financial results for Pacific Biosciences are anticipated to show an EPS of -$0.18, reflecting a 10% growth compared to the same quarter last year, with a revenue forecast of $36.46 million, indicating a 1.26% growth year-over-year [2] - For the annual period, the Zacks Consensus Estimates predict earnings of -$0.64 per share and revenue of $155.12 million, representing shifts of +22.89% and +0.72% respectively from the previous year [3] Group 3 - Recent modifications to analyst estimates for Pacific Biosciences indicate shifting dynamics in short-term business patterns, with upward revisions reflecting analysts' positive outlook on the company's operations and profit generation capabilities [4] - The Zacks Rank system, which assesses estimate changes, currently places Pacific Biosciences at a Zacks Rank of 3 (Hold), with an 8.36% increase in the consensus EPS estimate over the last 30 days [6] Group 4 - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 143, placing it within the bottom 42% of over 250 industries, indicating relative underperformance compared to higher-ranked industries [7]

Pacific Biosciences of California (PACB) FY Conference June 11, 2025 10:40 AM ET Speaker0 Great. Well, good morning, everyone. I'm Matt Sykes, life science tools and diagnostics analyst at Goldman Sachs. I have the pleasure of being joined, from PacBio, Jim Gibson, CFO, and Todd Friedman, senior director of IR. Jim, Todd, thanks for being here. Really appreciate it. Thanks, Matt. Maybe starting off, maybe just give everyone a brief background on the company and remind everyone kind of what some of the key p ...

Core Viewpoint - Pacific Biosciences of California, Inc. (PacBio) is experiencing growth driven by product development and strong first-quarter results, despite concerns over long purchasing cycles [1][11]. Company Performance - PacBio's shares have decreased by 43.8% year-to-date, compared to a 9.2% decline in the industry, while the S&P 500 Composite has increased by 0.8% [1]. - The company has a market capitalization of $315.1 million and projects a 19.3% growth for 2025, with earnings surpassing the Zacks Consensus Estimate in three of the last four quarters, averaging a surprise of 13.2% [2][12]. Product and Technology - PacBio's proprietary HiFi long-read sequencing technology, based on Single-Molecule Real-Time (SMRT) technology, enhances its market leadership by enabling high-accuracy detection of complex genomic structures [4]. - The global SMRT market is valued at $2.74 billion in 2023 and is expected to grow to $4.14 billion by 2031, with a CAGR of 5.3% [5]. - The introduction of the Onso system in 2022 and the Vega benchtop platform has expanded PacBio's offerings, allowing it to serve diverse research and clinical applications while reducing costs [5][8]. Financial Results - PacBio reported better-than-expected first-quarter results, with both earnings and revenues exceeding the Zacks Consensus Estimate, alongside a robust increase in service revenues [9]. - The company aims to achieve $45 to $50 million in annual cost savings through restructuring by the end of 2025 [6][10]. Market Challenges - PacBio faces longer purchasing cycles for its high-cost Revio sequencing system due to funding uncertainties and tighter capital budgets, particularly affecting academic and government institutions in the U.S. [11]. - Macroeconomic pressures in the Asia-Pacific region are also contributing to slower procurement timelines, which may impact near-term revenue growth [11].

Financial Data and Key Metrics Changes - The meeting addressed the formal business of the Annual Meeting of Stockholders, including the election of directors and the ratification of the independent registered public accounting firm [5][12] - Preliminary results indicated that the election of directors and the ratification of Ernst and Young LLP were approved [12][13] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed during the meeting [16] Market Data and Key Metrics Changes - No specific market data or key metrics were provided during the meeting [16] Company Strategy and Development Direction and Industry Competition - The board of directors recommended an amendment to the 2020 equity incentive plan to increase the number of shares reserved, which is aimed at attracting and retaining talent [10] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [16] Other Important Information - The meeting was held virtually in accordance with company bylaws and Delaware law, and the proxy statement was made available to stockholders prior to the meeting [5][6] Q&A Session Summary - There were no questions submitted during the Q&A session [16]

Pacific Biosciences of California (PACB) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Sinc ...

Core Viewpoint - PacBio has entered a strategic distribution agreement with Haorui Gene to enhance the adoption of its HiFi sequencing technology in China, particularly in clinical diagnostics and precision medicine [1][2][4]. Company Summary - The partnership with Haorui Gene allows PacBio to access a broader clinical laboratory network in China, which is expected to accelerate the adoption of its long-read sequencing platforms [1][4]. - PacBio's market capitalization is currently $294.4 million, with an anticipated earnings growth of 16.8% by 2025 [5]. - Following the announcement of the distribution agreement, PacBio's shares closed at $1.12, reflecting a year-to-date decline of 48.6% compared to the industry’s 9.7% decline [3]. Industry Summary - The global long-read sequencing market is projected to grow from an estimated size of $538.9 million in 2024, with a compound annual growth rate (CAGR) of 20.12% from 2025 to 2030 [12]. - Key drivers of market growth include the increasing prevalence of genetic diseases, the rise of personalized medicine, and advancements in technology leading to new sequencing methods [13].